{"content":"<li class=\"n-box-item date-title\" data-end=\"1500955199\" data-start=\"1500868800\" data-txt=\"Monday, December 23, 2019\">Monday, July 24, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3280753\" data-ts=\"1500938233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLB\" target=\"_blank\">CLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280753-core-labsminus-6-q2-revenues-come-up-short-q3-outlook-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Core Labs -6% as Q2 revenues come up short, Q3 outlook disappoints</a></h4><ul>     <li>Core Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/CLB' title='Core Laboratories'>CLB</a>) <font color='red'>-6.1%</font>&nbsp;AH after reporting <a href=\"http://www.prnewswire.com/news-releases/core-lab-reports-second-quarter-2017-results-300493234.html\" target=\"_blank\">Q2 earnings</a> of $0.51/share, in-line with the analyst consensus estimate of $0.51, and issuing below consensus Q3 guidance.</li>     <li>CLB says Q2 revenue of $164M, up 10.7%&nbsp;Y/Y but below analyst consensus of $168M, was slightly lower than previous guidance because of industry shortages of completion crews and equipment which caused fewer than expected completions, but an improvement in revenue mix generated higher operating margins.</li>     <li>CLB issues below consensus guidance for Q3, seeing EPS of  $0.54-$0.56 vs. $0.61 analyst consensus estimate on revenues of  $165.5M-$170M vs. $179M consensus.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280753\" data-linked=\"Core Labs -6% as Q2 revenues come up short, Q3 outlook disappoints\" data-tweet=\"$CLB - Core Labs -6% as Q2 revenues come up short, Q3 outlook disappoints https://seekingalpha.com/news/3280753-core-labsminus-6-q2-revenues-come-up-short-q3-outlook-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3280753-core-labsminus-6-q2-revenues-come-up-short-q3-outlook-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280750\" data-ts=\"1500936315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTI\" target=\"_blank\">FTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280750-technipfmc-to-restate-q1-after-overstating-net-income\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TechnipFMC to restate Q1 after overstating net income</a></h4><ul>     <li>TechnipFMC (NYSE:<a href='https://seekingalpha.com/symbol/FTI' title='TechnipFMC plc'>FTI</a>) <font color='red'>-1.5%</font> AH after disclosing that it will <a href=\"http://archive.fast-edgar.com//20170724/A722B22CZ22KH2Z2222A2MDZOTKKRZT28292/\" target=\"_blank\">restate its Q1 2017 financial statements</a> after overstating net income by $209M, or $0.45/share.</li>     <li>FTI says material weakness existed relating to the rates used in calculations of foreign currency effects on certain engineering and construction projects.</li>     <li>FTI says it has implemented additional controls and believes financial statements for the three- and six-month periods ending June 30 are reliable.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280750\" data-linked=\"TechnipFMC to restate Q1 after overstating net income\" data-tweet=\"$FTI - TechnipFMC to restate Q1 after overstating net income https://seekingalpha.com/news/3280750-technipfmc-to-restate-q1-after-overstating-net-income?source=tweet\" data-url=\"https://seekingalpha.com/news/3280750-technipfmc-to-restate-q1-after-overstating-net-income\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280749\" data-ts=\"1500935871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280749-tesla-powers-model-3-delivery-date\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla powers into Model 3 delivery date</a></h4><ul> <li>Shares of Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) finished <font color='green'>up 4.30%</font> as investors show confidence in front of the first batch of deliveries to Model 3 customers scheduled for this Friday.</li> <li>Amid the intense focus on Tesla's pace of production, the company <a href=\"http://www.sfchronicle.com/business/article/Tesla-faces-its-biggest-test-yet-with-Model-3-11307563.php\" target=\"_blank\">aims</a> to ramp up without sacrificing quality or safety. Musk and gang have pointed to the the simpler platform of the Model 3 in comparison to the Model X.</li><li>By next week, there should be more insight into the features, road performance, Autopilot capabilities and charging costs of the Model 3.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280749\" data-linked=\"Tesla powers into Model 3 delivery date\" data-tweet=\"$TSLA - Tesla powers into Model 3 delivery date https://seekingalpha.com/news/3280749-tesla-powers-model-3-delivery-date?source=tweet\" data-url=\"https://seekingalpha.com/news/3280749-tesla-powers-model-3-delivery-date\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280739\" data-ts=\"1500932811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280739-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/RMBS' title='Rambus, Inc.'>RMBS</a> <font color='green'>+1.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/TISI' title='Team, Inc.'>TISI</a> <font color='red'>-19.7%</font>. <a href='https://seekingalpha.com/symbol/SANM' title='Sanmina Corp'>SANM</a> <font color='red'>-9.3%</font>. <a href='https://seekingalpha.com/symbol/CLB' title='Core Laboratories'>CLB</a> <font color='red'>-5.9%</font>. <a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-3.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280739\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CDNS $RMBS $TISI - After Hours Gainers / Losers https://seekingalpha.com/news/3280739-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280739-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280727\" data-ts=\"1500930497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNS\" target=\"_blank\">CDNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280727-cadence-design-systems-beats-estimates-on-q2-and-guidance-shares-up-3_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cadence Design Systems beats estimates on Q2 and guidance; shares up 3.8%</a></h4><ul><li>        Cadence Design Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a>) reports Q2 results with revenue and EPS beats. Product and maintenance revenue was $443.8M, up from about $420M in the prior year&rsquo;s quarter, and Services reported $35.2M in sales compared to $33.1M. &nbsp;</li><li>        Q3 outlook has revenue between $475M and $485M and EPS between $0.33 to $0.35.Consensus estimates have revenue and EPS at $481.94 and $0.35, respectively</li><li>        FY17 outlook has revenue of $1.91B to $1.95B and $1.36 to $1.42 compared to the consensus $1.93B and $1.38.</li><li>Press release </li><li>Cadence shares are&nbsp;<font color='green'>up 3.79%</font>&nbsp;aftermarket. </li><li>Previously: <a href=\"https://seekingalpha.com/news/3280672-cadence-design-systems-beats-0_02-beats-revenue\" target=\"_blank\">Cadence Design Systems beats by $0.02, beats on revenue</a> (July 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280727\" data-linked=\"Cadence Design Systems beats estimates on Q2 and guidance; shares up 3.8%\" data-tweet=\"$CDNS - Cadence Design Systems beats estimates on Q2 and guidance; shares up 3.8% https://seekingalpha.com/news/3280727-cadence-design-systems-beats-estimates-on-q2-and-guidance-shares-up-3_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3280727-cadence-design-systems-beats-estimates-on-q2-and-guidance-shares-up-3_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280710\" data-ts=\"1500928786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280710-anadarko-petrominus-4-q2-bleeds-red-ink-cuts-2017-capex-300m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anadarko Petro -4% as Q2 bleeds red ink, cuts 2017 capex by $300M</a></h4><ul>     <li>Anadarko Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a>) <font color='red'>-4%</font> AH after reporting a steeper than expected <a href=\"https://seekingalpha.com/news/3280671-anadarko-petroleum-misses-0_42-beats-revenue\" target=\"_blank\">Q2 loss</a> and cutting its 2017 capital budget by $300M to an estimated $4.2B-$4.4B because of depressed oil prices.</li>     <li>\"Current market conditions require lower capital intensity given the volatility of margins realized in this operating environment. As such, we are reducing our level of investments by $300M for the full year, and adjusting full-year sales volume guidance to reflect recent  divestitures\" and deferred production related to the fatal home explosion in Colorado earlier this year that was linked to one of the company's wells.</li>     <li>APC says its Q2 total sales volumes rose 12% Y/Y to 57M boe, or 631K boe/day, which achieving record sales volume in the Delaware Basin averaging  ~33K boe/day, up 52% Y/Y.</li>     <li>APC also says it is in the final  stages of securing operatorship for ~70% of the Delaware Basin acreage position, which previously was part of the joint venture agreement that recently  concluded with Shell.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280710\" data-linked=\"Anadarko Petro -4% as Q2 bleeds red ink, cuts 2017 capex by $300M\" data-tweet=\"$APC - Anadarko Petro -4% as Q2 bleeds red ink, cuts 2017 capex by $300M https://seekingalpha.com/news/3280710-anadarko-petrominus-4-q2-bleeds-red-ink-cuts-2017-capex-300m?source=tweet\" data-url=\"https://seekingalpha.com/news/3280710-anadarko-petrominus-4-q2-bleeds-red-ink-cuts-2017-capex-300m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280706\" data-ts=\"1500928328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280706-alphabet-q2-shows-fine-impact-23-cost-per-click-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alphabet Q2 shows fine impact, 23% cost-per-click drop</a></h4><ul><li>Alphabet (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) announces Q2 results with revenue and EPS beats. The big news from the quarter was the accrued $2.7B EU antitrust fine, which shaved over $2.7B off operating income, nearly halved net income to $3.5B, and reduced EPS from $8.90 to the $5.01 that still beat consensus.</li><li>Key segment revenues: Google properties: $18.4B (<font color='green'>+20% Y/Y</font>); Google Network Members&rsquo; properties: $4.2B (<font color='green'>+14%</font>); Google advertising: $22.7B (<font color='green'>+18%</font>); Other Bets: $248M (<font color='green'>+34%</font>).</li><li>Aggregate paid clicks were&nbsp;<font color='green'>up 52%</font>&nbsp;on the year and&nbsp;<font color='green'>12%</font>&nbsp;on the prior quarter. Aggregate cost-per-click was&nbsp;<font color='red'>down 23%</font>&nbsp;on the year and&nbsp;<font color='red'>down 6%</font>&nbsp;on the quarter.</li><li><a href=\"https://abc.xyz/investor/news/earnings/2017/Q2_alphabet_earnings/\" target=\"_blank\">Press release</a></li><li>Alphabet Class A shares are&nbsp;<font color='red'>down 2.74%</font>&nbsp;and the Class C shares are&nbsp;<font color='red'>down 2.98%&nbsp;</font>aftermarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280662-alphabet-beats-0_58-beats-revenue\" target=\"_blank\">Alphabet beats by $0.58, beats on revenue</a> (July 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280706\" data-linked=\"Alphabet Q2 shows fine impact, 23% cost-per-click drop\" data-tweet=\"$GOOG $GOOG $GOOGL - Alphabet Q2 shows fine impact, 23% cost-per-click drop https://seekingalpha.com/news/3280706-alphabet-q2-shows-fine-impact-23-cost-per-click-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3280706-alphabet-q2-shows-fine-impact-23-cost-per-click-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280670\" data-ts=\"1500926808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JJSF\" target=\"_blank\">JJSF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280670-operating-income-declines-j-and-j-snacks-foods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Operating income declines at J&amp;J Snacks Foods</a></h4><ul>     <li>J&amp;J Snack Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/JJSF' title='J & J Snack Foods Corp.'>JJSF</a>) misses estimates with its <a href=\"https://seekingalpha.com/pr/16894481-j-and-j-snack-foods-reports-third-quarter-sales-earnings\" target=\"_blank\">Q2 report</a>. Operating income fell 1% to $81.2M during the quarter, despite the 6% top line growth.</li>     <li>CEO Gerald Schreiber says a shift in product mix in the food service segment impacted results.Operating income for the frozen beverages business was also lower</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3280665-j-and-j-snack-foods-misses-0_15-misses-revenue\" target=\"_blank\">J &amp; J Snack Foods misses by $0.15, misses on revenue</a> (July 24)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280670\" data-linked=\"Operating income declines at J&amp;J Snacks Foods\" data-tweet=\"$JJSF - Operating income declines at J&amp;J Snacks Foods https://seekingalpha.com/news/3280670-operating-income-declines-j-and-j-snacks-foods?source=tweet\" data-url=\"https://seekingalpha.com/news/3280670-operating-income-declines-j-and-j-snacks-foods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280668\" data-ts=\"1500926759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMBS\" target=\"_blank\">RMBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280668-rambus-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rambus beats by $0.01, beats on revenue</a></h4><ul><li>Rambus (NASDAQ:<a href='https://seekingalpha.com/symbol/RMBS' title='Rambus, Inc.'>RMBS</a>): Q2 EPS of $0.14 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $94.7M (+23.8% Y/Y) <font color='green'>beats by $1.7M</font>.</li><li>Shares <font color='green'>+3.7%</font>.</li><li><a href='https://seekingalpha.com/pr/16894512-rambus-reports-second-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280668\" data-linked=\"Rambus beats by $0.01, beats on revenue\" data-tweet=\"$RMBS - Rambus beats by $0.01, beats on revenue https://seekingalpha.com/news/3280668-rambus-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3280668-rambus-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280663\" data-ts=\"1500926292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280663-differing-views-on-plug-power-deal-wal-mart\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Differing views on Plug Power deal with Wal-Mart</a></h4><ul>     <li>Plug Power (<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='red'>-3.3%</font>) has given back a slice of Friday's big gains that followed news of its <a href=\"https://seekingalpha.com/news/3280228-plug-power-14-percent-new-wal-mart-deal\" target=\"_blank\">expanded deal</a> with Wal-Mart but shares remain only ~5% of 52-week highs.</li>     <li>Craig Hallum reiterates its Buy rating and $3 price target, as it believes Plug has removed a major overhang on the shares with the deal it views as further strong validation of the company's fuel cell and hydrogen fueling capabilities.</li>     <li>The firm say the deal reinforces the ties between both companies, signals an acceleration of WMT's growth and deployment plans, and creates another very motivated partner in WMT as it virtually replicates the existing agreement with  Amazon.</li>     <li>But Roth Capital keeps a Sell rating and $1.30 price target on PLUG, noting the deal includes the issuance of dilutive warrants, while the company also is eroding the quality of its future revenue, margins and earnings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280663\" data-linked=\"Differing views on Plug Power deal with Wal-Mart\" data-tweet=\"$PLUG - Differing views on Plug Power deal with Wal-Mart https://seekingalpha.com/news/3280663-differing-views-on-plug-power-deal-wal-mart?source=tweet\" data-url=\"https://seekingalpha.com/news/3280663-differing-views-on-plug-power-deal-wal-mart\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280657\" data-ts=\"1500925912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CL\" target=\"_blank\">CL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280657-analysts-weigh-in-on-colgate-palmolive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on Colgate-Palmolive</a></h4><ul> <li>Colgate-Palmolive (NYSE:<a href='https://seekingalpha.com/symbol/CL' title='Colgate-Palmolive Co.'>CL</a>) is <font color='red'>down 1.86%</font> after Morgan Stanley warns that the company faces long-term revenue pressures.</li> <li>In particular, the firm thinks the consumer trend of moving away from larger brands will hit Colgate-Palmolive's top line.</li> <li>Deutsche Bank was also out with comments today on the consumer products seller, <a href=\"https://www.streetinsider.com/Analyst+Comments/Colgate-Palmolive+%28CL%29%3A+Poor+Results+Increase+Likelihood+Of+Activist+Intervention+-+Deutsche+Bank/13121159.html\" target=\"_blank\">noting</a> that the poor results could increase the odds of activist investor action. DB rates Colgate-Palmolive at Neutral and assigns a price target of $75.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280657\" data-linked=\"Analysts weigh in on Colgate-Palmolive\" data-tweet=\"$CL - Analysts weigh in on Colgate-Palmolive https://seekingalpha.com/news/3280657-analysts-weigh-in-on-colgate-palmolive?source=tweet\" data-url=\"https://seekingalpha.com/news/3280657-analysts-weigh-in-on-colgate-palmolive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280656\" data-ts=\"1500925815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUN\" target=\"_blank\">SUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280656-sunoco-up-nearly-3-jana-partners-discloses-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunoco up nearly 3% as Jana Partners discloses stake</a></h4><ul><li>Calling Sunoco (<a href='https://seekingalpha.com/symbol/SUN' title='Sunoco LP'>SUN</a> <font color='green'>+2.9%</font>) a special situation, with downside support thanks to a well-covered dividend, and upside as investors better understand the recent 7-Eleven deal, Jana Partners tells its investors of a new stake in the company.</li><li>The 7-Eleven deal, says Jana, gives enough cash to reduce debt to manageable levels and cut the float enough to keep the per share distribution solid.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3280656\" data-linked=\"Sunoco up nearly 3% as Jana Partners discloses stake\" data-tweet=\"$SUN - Sunoco up nearly 3% as Jana Partners discloses stake https://seekingalpha.com/news/3280656-sunoco-up-nearly-3-jana-partners-discloses-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3280656-sunoco-up-nearly-3-jana-partners-discloses-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280645\" data-ts=\"1500922810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280645-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/INTT' title='inTest Corporation'>INTT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SGMA' title='SigmaTron International, Inc.'>SGMA</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SILC' title='Silicom Ltd'>SILC</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280645\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$CPAH $WBMD $INTT - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3280645-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280645-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280644\" data-ts=\"1500922479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280644-abbvie-on-hook-for-150m-for-falsely-advertising-testosterone-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie on the hook for $150M for falsely advertising testosterone therapy</a></h4><ul><li>AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-0.6%</font>) has ticked lower in the afternoon session on the heels of a <a href=\"https://www.law360.com/classaction/articles/947118\" target=\"_blank\">jury verdict</a> in a Chicago federal court where the company was defending itself in a lawsuit brought by an AndroGel user who claimed that the drug caused his heart attack and the company downplayed the risks.</li><li>The jury found that the company was not liable for his heart attack but awarded the plaintiff $150M in punitive damages on the basis of fraudulent misrepresentation. No compensatory damages were awarded.</li><li>Unsurprisingly, AbbVie disagrees with the verdict saying the plaintiff was an obese smoker who suffered from high blood pressure and cholesterol with a family history of heart disease. AbbVie counsel David Bernick adds, \"Together, these risk factors are completely sufficient to cause a heart attack.\"</li><li>This is the first verdict in multidistrict litigation over testosterone gel products involving thousands of lawsuits concentrated in Illinois federal court.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280644\" data-linked=\"AbbVie on the hook for $150M for falsely advertising testosterone therapy\" data-tweet=\"$ABBV - AbbVie on the hook for $150M for falsely advertising testosterone therapy https://seekingalpha.com/news/3280644-abbvie-on-hook-for-150m-for-falsely-advertising-testosterone-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3280644-abbvie-on-hook-for-150m-for-falsely-advertising-testosterone-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280636\" data-ts=\"1500919732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280636-credit-suisse-warns-on-chipotle-sentiment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse warns on Chipotle sentiment</a></h4><ul> <li>Credit Suisse reports back on what its online sentiment tracker revealed about Chipotle (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) following the restaurant chain's week of bad news.</li> <li>\"Not surprisingly, online sentiment plummeted in recent days. Daily net sentiment (a measure of \"positive\" vs. \"negative\" online commentary) fell from 55 on July 17, to -11 on July 18. Sentiment \"improved\" to 12 and 16 on July 19 and July 20, resp., though these are still depressed figures by historical standards.\"</li> <li>The Credit Suisse sentiment data has had a +76% correlation with Chipotle's same-store sales performance since the 2015 food safety crisis.</li> <li>The firm lowers its price target on Chipotle to $325 from $425 after taking in the most recent sentiment read. The PT is 18X the CS estimate on CMG's 2018 EBITDA.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280636\" data-linked=\"Credit Suisse warns on Chipotle sentiment\" data-tweet=\"$CMG - Credit Suisse warns on Chipotle sentiment https://seekingalpha.com/news/3280636-credit-suisse-warns-on-chipotle-sentiment?source=tweet\" data-url=\"https://seekingalpha.com/news/3280636-credit-suisse-warns-on-chipotle-sentiment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280633\" data-ts=\"1500919263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280633-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials'>RYAM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GPP' title='Green Plains Partners'>GPP</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280633\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$RYAM $GPP $TRNX - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3280633-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280633-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280621\" data-ts=\"1500916014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMTX\" target=\"_blank\">DMTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280621-finance-chief-dimension-therapeutics-bids-adieu-shares-ease-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finance chief at Dimension Therapeutics bids adieu; shares ease 2%</a></h4><ul><li>Dimension Therapeutics (<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-1.8%</font>) Chief Financial Officer, Secretary and Treasurer Jean Franchi <a href=\"https://www.sec.gov/Archives/edgar/data/1592288/000119312517233265/d430894d8k.htm\" target=\"_blank\">resigns </a>effective July 28. COO Mary Thistle will take on the role of principal financial and accounting officer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275828-dimension-therapeutics-sharpens-focus-key-programs-25-percent-headcount-cut-year-end-shares\" target=\"_blank\">Dimension Therapeutics sharpens focus on key programs, 25% headcount cut by year-end; shares ahead 7%</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280621\" data-linked=\"Finance chief at Dimension Therapeutics bids adieu; shares ease 2%\" data-tweet=\"$DMTX - Finance chief at Dimension Therapeutics bids adieu; shares ease 2% https://seekingalpha.com/news/3280621-finance-chief-dimension-therapeutics-bids-adieu-shares-ease-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280621-finance-chief-dimension-therapeutics-bids-adieu-shares-ease-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280619\" data-ts=\"1500915886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280619-hedgeye-picks-retail-winners-and-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hedgeye picks retail winners and losers</a></h4><ul> <li>Hedgeye isn't scared to make some calls in the retail sector, saying the consensus call of the 'Amazon'ism of the retail world is wrong.</li> <li>The firm names Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-1.7%</font>), Dick's Sporting Goods (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color='red'>-4.3%</font>), Coach (COH <font color='red'>-0.3%</font>), Wal-Mart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> <font color='green'>+1.1%</font>) and Restoration Hardware (<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+1.2%</font>)&nbsp;as its best longs in the sector.</li> <li>Short ideas from Hedgeye include Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-2.1%</font>), Hanesbrands (<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a> <font color='red'>-1.3%</font>), Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='red'>-1.2%</font>), Wayfair (<a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a> <font color='green'>+0.5%</font>), Ralph Lauren (<a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a> <font color='red'>-2.8%</font>), Under Armour (<a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='red'>-2%</font>), Carter's (<a href='https://seekingalpha.com/symbol/CRI' title='Carter&#39;s, Inc.'>CRI</a> <font color='red'>-1.3%</font>), Williams-Sonoma (<a href='https://seekingalpha.com/symbol/WSM' title='Williams-Sonoma Inc.'>WSM</a> <font color='red'>-1.1%</font>) and Party City (<a href='https://seekingalpha.com/symbol/PRTY' title='Party City Holdco, Inc.'>PRTY</a> <font color='red'>-2.4%</font>).</li> <li><a href=\"https://app.hedgeye.com/insights/60615-stock-talk-live-with-retail-sector-brian-mcgough-at-2-30pm-et?subtype=tv-ticker-talk&amp;type=hedgeye-tv\" target=\"_blank\">Hedgeye's Brian McGough video interview on the retail sector</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280619\" data-linked=\"Hedgeye picks retail winners and losers\" data-tweet=\"$NKE $NKE $DKS - Hedgeye picks retail winners and losers https://seekingalpha.com/news/3280619-hedgeye-picks-retail-winners-and-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280619-hedgeye-picks-retail-winners-and-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280618\" data-ts=\"1500915866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280618-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HIFR' title='InfraREIT'>HIFR</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280618\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$HIFR $GLA - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3280618-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280618-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280608\" data-ts=\"1500915120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMS\" target=\"_blank\">SGMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280608-casino-stocks-rally-after-strong-scientific-games-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Casino stocks rally after strong Scientific Games report</a></h4><ul>     <li>Investors are snapping shares of casino stocks after Scientific Games (<a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corp'>SGMS</a> <font color='green'>+22.9%</font>) posted strong Q2 results.</li>     <li>Gaming machine sales revenue increased 6% Y/Y for Scientific Games during the quarter, despite no new casino openings. The company's shipments were up 24% in the U.S. and Canada for replacement machines.</li>     <li>Notable gainers include Penn National Gaming (<a href='https://seekingalpha.com/symbol/PENN' title='Penn National Gaming, Inc.'>PENN</a> <font color='green'>+3.5%</font>), Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='green'>+3.3%</font>), Caesars Acquisition Company (<a href='https://seekingalpha.com/symbol/CACQ' title='Caesars Acquisition Company'>CACQ</a> <font color='green'>+2.5%</font>), Caesars Entertainment (<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment'>CZR</a> <font color='green'>+2.4%</font>), Empire Resorts (<a href='https://seekingalpha.com/symbol/NYNY' title='Empire Resorts, Inc.'>NYNY</a> <font color='green'>+1.9%</font>), Boyd Gaming (<a href='https://seekingalpha.com/symbol/BYD' title='Boyd Gaming Corporation'>BYD</a> <font color='green'>+1.7%</font>), Pinnacle Entertainment (<a href='https://seekingalpha.com/symbol/PNK' title='Pinnacle Entertainment, Inc.'>PNK</a> <font color='green'>+2.2%</font>) and Eldorado Resorts (<a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a> <font color='green'>+1%</font>).</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/BJK' title='VanEck Vectors Gaming ETF'>BJK</a>.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3280454-scientific-games-beats-0_08-beats-revenue\" target=\"_blank\">Scientific Games beats by $0.08, beats on revenue</a> (July 24)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280608\" data-linked=\"Casino stocks rally after strong Scientific Games report\" data-tweet=\"$SGMS $SGMS $PENN - Casino stocks rally after strong Scientific Games report https://seekingalpha.com/news/3280608-casino-stocks-rally-after-strong-scientific-games-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3280608-casino-stocks-rally-after-strong-scientific-games-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280607\" data-ts=\"1500914577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAH-OLD\" target=\"_blank\">PAH-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280607-reuters-platform-specialty-may-get-4b-plus-offer-for-agrochemicals-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Platform Specialty may get $4B-plus offer for agrochemicals unit</a></h4><ul>     <li>Platform Specialty Services (<a href='https://seekingalpha.com/symbol/PAH-OLD' title='Platform Specialty Products Corp'>PAH-OLD</a> <font color='green'>+5.3%</font>) jumps following a Reuters report that Indian agrochemicals producer UPL Ltd. is <a href=\"http://www.reuters.com/article/us-platform-splty-m-a-upl-exclusive-idUSKBN1A921Q\" target=\"_blank\">exploring a $4B-plus bid</a> for PAH's agrochemicals business.</li>     <li>UPL is in talks with P-E firm New Mountain Capital about teaming up on an offer, and would challenge a rival offer for the unit by a P-E consortium of Blackstone (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='green'>+0.5%</font>) and CVC Capital Partners, according to the report.</li>     <li>A competition would be welcomed by PAH and its biggest shareholder, Bill Ackman's Pershing Square hedge fund, which owns 14.5% of the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280607\" data-linked=\"Reuters: Platform Specialty may get $4B-plus offer for agrochemicals unit\" data-tweet=\"$PAH-OLD $PAH-OLD $BX - Reuters: Platform Specialty may get $4B-plus offer for agrochemicals unit https://seekingalpha.com/news/3280607-reuters-platform-specialty-may-get-4b-plus-offer-for-agrochemicals-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3280607-reuters-platform-specialty-may-get-4b-plus-offer-for-agrochemicals-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280606\" data-ts=\"1500914494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280606-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corp'>SGMS</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/NDRM' title='NeuroDerm'>NDRM</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYTX' title='Cytori Therapeutics Inc'>CYTX</a> <font color='red'>-58%</font>. <a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280606\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SGMS $RETA $HEBT - Midday Gainers / Losers https://seekingalpha.com/news/3280606-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280606-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280603\" data-ts=\"1500914195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280603-napo-pharma-announces-positive-data-on-hiv-diarrheal-product-mytesi-merger-partner-jaguar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Napo Pharma announces positive data on HIV diarrheal product Mytesi; merger partner Jaguar Animal Health up 2%</a></h4><ul><li>Jaguar Animal Health (<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color='green'>+1.5%</font>) inches up modestly higher volume after an <a href=\"https://seekingalpha.com/pr/16893991-new-data-shows-dramatic-reduction-chronic-diarrhea-episodes-crofelemer-mytesi-treatment\" target=\"_blank\">announcement </a>by planned merger partner Napo Pharmaceuticals about HIV-related diarrhea product Mytesi (crofelemer).</li><li>A supplemental analysis of a long-term study showed treatment with Mytesi lowered the average number of diarrhea episodes in HIV patients 70% from baseline with half completely resolving their diarrhea. The data were presented at the 9th IAS Conference on HIV Science in Paris.</li><li>Napo launched Mytesi in October 2016. Crofelemer is also the active ingredient in Jaguar's Canalevia for the treatment of acute diarrhea in dogs.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3241867-jaguar-animal-health-merge-napo-pharmaceuticals\" target=\"_blank\">Jaguar Animal Health to merge with Napo Pharmaceuticals</a> (Feb. 8)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3214557-jaguar-animal-healths-lead-product-candidate-shows-statistically-valid-effect-proof-concept\" target=\"_blank\">Jaguar Animal Health's lead product candidate shows statistically valid effect in proof-of-concept study; shares ahead 5%</a> (Oct. 18, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280603\" data-linked=\"Napo Pharma announces positive data on HIV diarrheal product Mytesi; merger partner Jaguar Animal Health up 2%\" data-tweet=\"$JAGX - Napo Pharma announces positive data on HIV diarrheal product Mytesi; merger partner Jaguar Animal Health up 2% https://seekingalpha.com/news/3280603-napo-pharma-announces-positive-data-on-hiv-diarrheal-product-mytesi-merger-partner-jaguar?source=tweet\" data-url=\"https://seekingalpha.com/news/3280603-napo-pharma-announces-positive-data-on-hiv-diarrheal-product-mytesi-merger-partner-jaguar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280604\" data-ts=\"1500913693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280604-ges-2017-guidance-was-painful-necessary-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE&#39;s 2017 guidance was painful but necessary, analyst says</a></h4><ul>     <li>As another down day unfolds for General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-1.6%</font>), the company is now the Dow's worst performer YTD, shedding -19.4% so far vs. Verizon's loss of 17.8%.</li>     <li>RBC analyst Deane Dray writes that outgoing CEO&nbsp;Jeffrey Immelt \"<a href=\"http://www.barrons.com/articles/general-electric-there-goes-the-band-aid-1500905606\" target=\"_blank\">ripped the band-aid</a>\" by <a href=\"https://seekingalpha.com/news/3280297-ge-minus-4_5-percent-open-immelt-warns-oil-gas-weakness\" target=\"_blank\">cutting full-year guidance</a> during Friday's <a href=\"https://seekingalpha.com/article/4089530-general-electrics-ge-ceo-jeff-immelt-q2-2017-results-earnings-call-transcript\" target=\"_blank\">earnings conference call</a>, but he believes the \"guidance cuts were necessary to remove an overhang and reset expectations.\"</li>     <li>\"Although the official axe has not yet fallen on the much-scrutinized $2.00 2018 EPS target (set in 2015), the market has already similarly moved on,\" according to Dray.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280604\" data-linked=\"GE&#39;s 2017 guidance was painful but necessary, analyst says\" data-tweet=\"$GE - GE&#39;s 2017 guidance was painful but necessary, analyst says https://seekingalpha.com/news/3280604-ges-2017-guidance-was-painful-necessary-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3280604-ges-2017-guidance-was-painful-necessary-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280595\" data-ts=\"1500912182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280595-ad-com-approaches-for-intellipharmaceutics-marketing-application-for-abuse-deterrent-extended\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Com approaches for Intellipharmaceutics&#39; marketing application for abuse-deterrent extended-release oxycodone; shares off 10% as investors digest briefing docs</a></h4><ul><li>A <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm565584.htm\" target=\"_blank\">joint meeting</a> of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will take place on Wednesday, July 26 to review and discuss Intellipharmaceutics' (<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='red'>-10.4%</font>) New Drug Application &#40;NDA&#41; seeking approval of an abuse-deterrent formulation of extended-release oxycodone hydrochloride for the treatment of severe chronic pain.</li><li>Shares are down on almost a 5x surge in volume indicating perceived risk to a positive vote.</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568075.pdf\" target=\"_blank\">FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568076.pdf\" target=\"_blank\">Errata to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568079.pdf\" target=\"_blank\">Company briefing doc</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280595\" data-linked=\"Ad Com approaches for Intellipharmaceutics&#39; marketing application for abuse-deterrent extended-release oxycodone; shares off 10% as investors digest briefing docs\" data-tweet=\"$IPCI - Ad Com approaches for Intellipharmaceutics&#39; marketing application for abuse-deterrent extended-release oxycodone; shares off 10% as investors digest briefing docs https://seekingalpha.com/news/3280595-ad-com-approaches-for-intellipharmaceutics-marketing-application-for-abuse-deterrent-extended?source=tweet\" data-url=\"https://seekingalpha.com/news/3280595-ad-com-approaches-for-intellipharmaceutics-marketing-application-for-abuse-deterrent-extended\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280599\" data-ts=\"1500912149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280599-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SANW' title='S&W Seed Co'>SANW</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CALM' title='Cal-Maine Foods, Inc.'>CALM</a> <font color='red'>-7%</font>. AOI <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280599\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SANW $BETR-OLD $HAS - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3280599-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280599-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280594\" data-ts=\"1500911607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POR\" target=\"_blank\">POR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280594-portland-general-electric-cut-to-sell-williams-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portland General Electric cut to Sell at Williams Capital</a></h4><ul>     <li>Portland General Electric (<a href='https://seekingalpha.com/symbol/POR' title='Portland General Electric Company'>POR</a> <font color='red'>-2.5%</font>) is <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Williams+Capital+Downgrades+Portland+General+Electric+Company+%28POR%29+to+Hold/13121134.html\" target=\"_blank\">downgraded to Sell</a> from Hold with a $41 price target, trimmed from $44, at Williams Capital, which says POR's once-strong case for significant growth over the next few years has dwindled considerably.</li>     <li>Oregon's PUC  staff has recommended both a poor outcome from the IRP and a rate cut in the pending base rate case in its initial June 16 testimony, and Williams says current consensus expectations do not appear to reflect what is clearly disappointing results from either the IRP or rate case dockets.</li>     <li>The firm sees limited residential load growth at best and often declining weather adjusted load with rising operating expenses, thus near-term EPS growth will be difficult to achieve absent a rate case or IRP/RFP successes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280594\" data-linked=\"Portland General Electric cut to Sell at Williams Capital\" data-tweet=\"$POR - Portland General Electric cut to Sell at Williams Capital https://seekingalpha.com/news/3280594-portland-general-electric-cut-to-sell-williams-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3280594-portland-general-electric-cut-to-sell-williams-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280589\" data-ts=\"1500910823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANGO\" target=\"_blank\">ANGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280589-angiodynamics-up-8-on-ceo-share-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AngioDynamics up 8% on CEO share buy</a></h4><ul><li>Buying has ticked up in thinly traded AngioDynamics (<a href='https://seekingalpha.com/symbol/ANGO' title='AngioDynamics, Inc.'>ANGO</a> <font color='green'>+7.9%</font>) in apparent response to a <a href=\"http://www.4-traders.com/ANGIODYNAMICS-INC-8379/news/AngioDynamics-Insider-Trading-Activity-AngioDynamics-Inc-ndash-CEO-Bought-5-000-shares-of-Stoc-24803242/\" target=\"_blank\">5K-share purchase</a>&nbsp;at $15.79 by CEO James Clemmer on Friday.</li><li>Last month, the FDA cleared its Solero Microwave Tissue Ablation System which is used to ablate soft tissue during open procedures (not cardiac).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272062-angiodynamics-announces-fda-clearance-solero-mta-system\" target=\"_blank\">AngioDynamics announces FDA clearance for the Solero MTA System</a> (June 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280589\" data-linked=\"AngioDynamics up 8% on CEO share buy\" data-tweet=\"$ANGO - AngioDynamics up 8% on CEO share buy https://seekingalpha.com/news/3280589-angiodynamics-up-8-on-ceo-share-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3280589-angiodynamics-up-8-on-ceo-share-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280583\" data-ts=\"1500909331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSUR\" target=\"_blank\">OSUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280583-orasures-rapid-hiv-self-test-selected-for-study-in-africa-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OraSure&#39;s rapid HIV self-test selected for study in Africa; shares up 2%</a></h4><ul><li>UNITAID and Population Services International have&nbsp;<a href=\"https://seekingalpha.com/pr/16893767-oraquick-hiv-self-test-selected-next-phase-star-project-hiv-self-testing-africa\" target=\"_blank\">selected</a> OraSure Technologies' (<a href='https://seekingalpha.com/symbol/OSUR' title='OraSure Technologies, Inc.'>OSUR</a> <font color='green'>+1.9%</font>) OraQuick HIV Self-Test for use in the second phase of the HIV Self-Testing Africa &#40;STAR&#41; Project.</li><li>Starting in Q4, STAR will deploy HIV Self-Testing in Malawi, Zambia, Zimbabwe, South Africa and certain other African countries to demonstrate the population-level health impact of HIV self-testing over a two-year period. OraSure says the vast majority of the 4M tests used in Phase 2 will be OraQuick.</li><li>750K OraQuick HIV Self-Tests were distributed in Phase 1 of the project.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280583\" data-linked=\"OraSure&#39;s rapid HIV self-test selected for study in Africa; shares up 2%\" data-tweet=\"$OSUR - OraSure&#39;s rapid HIV self-test selected for study in Africa; shares up 2% https://seekingalpha.com/news/3280583-orasures-rapid-hiv-self-test-selected-for-study-in-africa-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280583-orasures-rapid-hiv-self-test-selected-for-study-in-africa-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280560\" data-ts=\"1500908626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280560-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NDRM' title='NeuroDerm'>NDRM</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYTX' title='Cytori Therapeutics Inc'>CYTX</a> <font color='red'>-60%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280560\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$RETA $NVAX $NDRM - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3280560-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3280560-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280578\" data-ts=\"1500908319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAL\" target=\"_blank\">HAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280578-halliburton-turns-red-u-s-shale-firms-tapping-brakes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halliburton turns red as U.S. shale firms &quot;tapping the brakes&quot;</a></h4><ul>     <li>Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='red'>-3.2%</font>) has turned sharply lower after its earnings conference call, as Chairman Dave Lesar said rig count growth is showing signs of plateauing and North American customers are \"<a href=\"http://www.reuters.com/article/us-halliburton-results-idUSKBN1A9189?il=0\" target=\"_blank\">tapping the brakes</a>.\"</li>     <li>HAL says its pressure pumping equipment is sold out in Q3 and it has been successful passing along supply cost increases to its customers, but Q2 saw the first  decline in years in average sand pumped per well.</li>     <li>HAL also expects margins in its completion and production division to increase by 225-325 basis points in Q3.</li>     <li>However, the company does not expect a near-term rebound in the international markets for several reasons, including the lengthy contracting cycles that will mute any near-term pricing inflection, and a lack of confidence in commodity prices in order to overcome the duration risk in their projects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280578\" data-linked=\"Halliburton turns red as U.S. shale firms &quot;tapping the brakes&quot;\" data-tweet=\"$HAL - Halliburton turns red as U.S. shale firms &quot;tapping the brakes&quot; https://seekingalpha.com/news/3280578-halliburton-turns-red-u-s-shale-firms-tapping-brakes?source=tweet\" data-url=\"https://seekingalpha.com/news/3280578-halliburton-turns-red-u-s-shale-firms-tapping-brakes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280577\" data-ts=\"1500907996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DECK\" target=\"_blank\">DECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280577-susquehanna-cautious-on-deckers-outdoor-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna cautious on Deckers Outdoor sale</a></h4><ul> <li>Susquehanna analyst Sam Poser reduces his price target on Neutral-rated Deckers Outdoor (<a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a> <font color='red'>-3.5%</font>) to <a href=\"https://www.streetinsider.com/Analyst+Comments/Deckers+Outdoor+%28DECK%29%3A+Cutting+PT+To+%2457+From+%2460+-+Susquehanna/13120956.html\" target=\"_blank\">$57</a> from $60 due to a lower assessment on the odds of a sale. Activist investors Red Mountain Capital Partners and Marcato Capital Management have both been pushing the retailer to explore sale options.</li> <li>Poser also points to the ongoing challenges for Deckers with the Ugg brand.</li><li>Shares of Deckers are up 16% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280577\" data-linked=\"Susquehanna cautious on Deckers Outdoor sale\" data-tweet=\"$DECK - Susquehanna cautious on Deckers Outdoor sale https://seekingalpha.com/news/3280577-susquehanna-cautious-on-deckers-outdoor-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3280577-susquehanna-cautious-on-deckers-outdoor-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280574\" data-ts=\"1500907155\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RETA\" target=\"_blank\">RETA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280574-reatas-bardoxolone-methyl-shows-treatment-effect-in-mid-stage-kidney-disease-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reata&#39;s bardoxolone methyl shows treatment effect in mid-stage kidney disease study; shares ahead 20%</a></h4><ul><li>Thinly traded nano cap Reata Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color='green'>+19.6%</font>) heads north on almost a 5x surge in volume, albeit on turnover of only 400K shares, in response to its <a href=\"https://seekingalpha.com/pr/16893728-reata-s-bardoxolone-methyl-demonstrated-improved-kidney-function-patients-alport-syndrome\" target=\"_blank\">announcement </a>of positive results from the open-label Phase 2 portion of its Phase 2/3 clinical trial, CARDINAL, assessing bardoxolone methyl in patients with chronic kidney disease &#40;CKD&#41; caused by Alport syndrome.</li><li>The data showed treatment with bardoxolone produced a statistically significant improvement in kidney function from baseline in all 30 participants as measured by estimated glomerular filtration rate (eGFR). The average improvement was 12.6% at week 4 and 23.2% at week 12.</li><li>The company has initiated screening for the Phase 3 portion, which will enroll ~150 subjects. The eGFR change will be measured after 48 weeks' treatment and again after 52 weeks after a four-week withdrawal period. Management says the FDA has indicated that a retained one-year eGFR benefit could support accelerated approval.</li><li>It also plans to launch new Phase 2 trials in rare renal diseases in H1 2018.</li><li>Alport syndrome is a genetic disorder that causes CKD that affects ~12K Americans. Almost all will develop end-stage renal disease.</li><li><a href=\"http://reatapharma.com/product-pipeline/cardiovascular/bardpulmonary-hypertension-ild-ctd/\" target=\"_blank\">Bardoxolone methyl</a>&nbsp;is an experimental oral once-daily antioxidant inflammation modulator that targets the&nbsp;<a href=\"https://en.wikipedia.org/wiki/NFE2L2\" target=\"_blank\">Nrf2 pathway</a>, a regulator of antioxidant proteins that protect against oxidative damage associated with injury or inflammation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280574\" data-linked=\"Reata&#39;s bardoxolone methyl shows treatment effect in mid-stage kidney disease study; shares ahead 20%\" data-tweet=\"$RETA - Reata&#39;s bardoxolone methyl shows treatment effect in mid-stage kidney disease study; shares ahead 20% https://seekingalpha.com/news/3280574-reatas-bardoxolone-methyl-shows-treatment-effect-in-mid-stage-kidney-disease-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3280574-reatas-bardoxolone-methyl-shows-treatment-effect-in-mid-stage-kidney-disease-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280573\" data-ts=\"1500906806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280573-macau-revenue-expected-to-be-strong-in-july\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macau revenue expected to be strong in July</a></h4><ul> <li>Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='green'>+2.5%</font>) and Melco Resorts &amp; Entertainment (<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited ADR'>MLCO</a> <font color='green'>+1.6%</font>) trade strong after Nomura Instinet increases its <a href=\"https://www.bloomberg.com/news/articles/2017-07-24/hong-kong-stocks-advance-to-two-year-high-amid-mainland-inflows\" target=\"_blank\">forecast</a> for Macau gaming revenue in July to +28% from +25%.</li> <li>There's also a positive note out from Union Gaming Group in the mix. \"We believe shares will continue to respond to strong levels of gross gaming revenue growth in the market despite all of the recent noise surrounding capital controls, which have not had a measurable impact on Macau,\" advises Union analyst Grant Govertsen.</li> <li>MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='green'>+0.9%</font>) and Las Vegas Sands (<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a> <font color='green'>+0.7%</font>) are also ahead of broad market averages on the day.</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/BJK' title='VanEck Vectors Gaming ETF'>BJK</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280573\" data-linked=\"Macau revenue expected to be strong in July\" data-tweet=\"$WYNN $WYNN $MLCO - Macau revenue expected to be strong in July https://seekingalpha.com/news/3280573-macau-revenue-expected-to-be-strong-in-july?source=tweet\" data-url=\"https://seekingalpha.com/news/3280573-macau-revenue-expected-to-be-strong-in-july\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280570\" data-ts=\"1500905294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280570-delmar-pharma-on-go-in-china-mid-stage-study-of-lead-candidate-valminus-083-in-brain-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DelMar Pharma on go in China with mid-stage study of lead candidate VAL-083 in brain cancer; shares ahead 1%</a></h4><ul><li>DelMar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='green'>+1.4%</font>) <a href=\"https://seekingalpha.com/pr/16893916-delmar-pharmaceuticals-receives-approval-chinas-human-genetic-resources-administration\" target=\"_blank\">reports </a>that the Human Genetic Resources Administration of China &#40;HGRAC&#41; has approved its application to launch a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03050736?term=NCT03050736&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating lead product candidate VAL-083 in patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme &#40;GBM&#41;, a subpopulation of ~67% of GBM patients. HGRAC had to bless the study because it will use MGMT (enzyme O6-methylguanine methyltransferase) status as a biomarker for patient selection and enrollment.</li><li>Results from the study will inform the design of global trials. The company says that the studies, if successful, could position VAL-083 as a replacement for current standard-of-care chemoradiation + temozolomide.</li><li>Enrollment should commence in the coming weeks at a medical center in Guangzhou. According to ClinicalTrials.gov, the estimated primary completion date is February 2019.</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280570\" data-linked=\"DelMar Pharma on go in China with mid-stage study of lead candidate VAL-083 in brain cancer; shares ahead 1%\" data-tweet=\"$DMPI - DelMar Pharma on go in China with mid-stage study of lead candidate VAL-083 in brain cancer; shares ahead 1% https://seekingalpha.com/news/3280570-delmar-pharma-on-go-in-china-mid-stage-study-of-lead-candidate-valminus-083-in-brain-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3280570-delmar-pharma-on-go-in-china-mid-stage-study-of-lead-candidate-valminus-083-in-brain-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280561\" data-ts=\"1500904330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIBB\" target=\"_blank\">HIBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280561-hibbett-sales-warning-hits-retail-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hibbett sales warning hits retail sector</a></h4><ul> <li>Weak sales guidance from Hibbett Sports (<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='red'>-26.6%</font>) is rattling around the sensitive sporting goods sector.</li> <li>Dick's is <font color='red'>down 3.39%</font>, while Sportsman's Warehouse (<a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-5.6%</font>), Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='red'>-2.9%</font>), Finish Line (<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-3.6%</font>), DSW (<a href='https://seekingalpha.com/symbol/DSW' title='DSW Inc.'>DSW</a> <font color='red'>-1.6%</font>), Caleres (<a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='red'>-1.2%</font>), Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='red'>-3.9%</font>), Deckers Outdoor (<a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a> <font color='red'>-2.7%</font>) and Wolverine World Wide (<a href='https://seekingalpha.com/symbol/WWW' title='Wolverine World Wide Inc.'>WWW</a> <font color='red'>-1.7%</font>) are some of the other sports-related retail chains under pressure.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280478-hibbett-sports-posts-q2-sales-update\" target=\"_blank\">Hibbett Sports posts Q2 sales update</a> (July 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280502-weak-results-hibbett-sports-hit-sports-retail-sector\" target=\"_blank\">Weak results from Hibbett Sports hit sports retail sector</a> (July 24)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280561\" data-linked=\"Hibbett sales warning hits retail sector\" data-tweet=\"$HIBB $HIBB $SPWH - Hibbett sales warning hits retail sector https://seekingalpha.com/news/3280561-hibbett-sales-warning-hits-retail-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3280561-hibbett-sales-warning-hits-retail-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280556\" data-ts=\"1500903886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAM\" target=\"_blank\">SAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280556-boston-beer-lower-after-goldman-sachs-warns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boston Beer lower after Goldman Sachs warns</a></h4><ul> <li>Boston Beer (NYSE:<a href='https://seekingalpha.com/symbol/SAM' title='Boston Beer Co.'>SAM</a>) is <font color='red'>down 4.55%</font> in early trading after Goldman Sachs drops its forecast for total U.S. beer volume for 2017-2018 to -0.7% to -0.3% vs. 0% to +0.1% prior.</li> <li>Beyond the broad volume concerns, Boston Beer also faces slower growth rates for its craft brands and increased competition from imports.</li> <li>Goldman <a href=\"https://seekingalpha.com/news/3280425-stocks-watch-next-week\" target=\"_blank\">cuts</a>&nbsp;the beer company to Sell from Neutral and slashes the price target to $110 from $140.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280556\" data-linked=\"Boston Beer lower after Goldman Sachs warns\" data-tweet=\"$SAM - Boston Beer lower after Goldman Sachs warns https://seekingalpha.com/news/3280556-boston-beer-lower-after-goldman-sachs-warns?source=tweet\" data-url=\"https://seekingalpha.com/news/3280556-boston-beer-lower-after-goldman-sachs-warns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280554\" data-ts=\"1500903407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NPTN\" target=\"_blank\">NPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280554-neophotonicsminus-2_6-raymond-james-takes-off-strong-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoPhotonics -2.6% as Raymond James takes off Strong Buy</a></h4><ul>   <li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) is <font color='red'>off 2.6%</font> after Raymond James trimmed some heavy bullishness on shares.</li>    <li>The firm downgraded shares to Outperform, down from a previous Strong Buy recommendation. It joins more than a half-dozen other analyst firms recommending Buys.</li>    <li>Raymond James has a price target of $9, implying 9.6% upside from today's lower price.</li>    <li>NeoPhotonics reports earnings Aug. 3 after the closing bell.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280554\" data-linked=\"NeoPhotonics -2.6% as Raymond James takes off Strong Buy\" data-tweet=\"$NPTN - NeoPhotonics -2.6% as Raymond James takes off Strong Buy https://seekingalpha.com/news/3280554-neophotonicsminus-2_6-raymond-james-takes-off-strong-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3280554-neophotonicsminus-2_6-raymond-james-takes-off-strong-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280544\" data-ts=\"1500902531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280544-pandoraplus-4_5-on-report-jana-partners-new-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora +4.5% on report Jana Partners has new stake</a></h4><ul>   <li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) is <font color='green'>up 4.5%</font> premarket after Bloomberg notes a source says Jana Partners has revealed a new stake in the company in a letter.</li>    <li>Shares are <font color='red'>down 27.4%</font> in 2017, and <font color='red'>down 22.9%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280544\" data-linked=\"Pandora +4.5% on report Jana Partners has new stake\" data-tweet=\"$P - Pandora +4.5% on report Jana Partners has new stake https://seekingalpha.com/news/3280544-pandoraplus-4_5-on-report-jana-partners-new-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3280544-pandoraplus-4_5-on-report-jana-partners-new-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280540\" data-ts=\"1500902141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280540-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+28%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16893959-court-denies-plaintiffs-request-preliminary-injunction\" target=\"_blank\">order</a> denying Plaintiff&nbsp;Michael Sammons'&nbsp;motion for a preliminary injunction.</li><li><a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a> <font color='green'>+20%</font>&nbsp;on releasing Q2 prelim <a href=\"https://seekingalpha.com/news/3280492-webmd-provides-preliminary-q2-results-shares-ahead-20-percent-premarket\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/NDRM' title='NeuroDerm'>NDRM</a> <font color='green'>+16%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3280453-neuroderm-bought-mitsubishi-tanabe-pharma-39-share\" target=\"_blank\">acquired</a> by Mitsubishi Tanabe Pharma.</li><li><a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='green'>+12%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3280484-genocea-reports-positive-top-line-12-month-phase-2b-data-genminus-003-genital-herpes-shares\" target=\"_blank\">reporting</a> positive top-line 12-month Phase 2b data for GEN-003 in genital herpes.</li><li><a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>&nbsp;<font color='green'>+9%</font>&nbsp;on positive <a href=\"https://seekingalpha.com/news/3280474-blue-apron-rallies-analyst-coverage-starts\" target=\"_blank\">rating</a> by analyst.</li><li><a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='green'>+7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280540\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DRYS $WBMD $NDRM - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3280540-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3280540-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280539\" data-ts=\"1500902132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280539-citi-warns-on-restoration-hardware\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi warns on Restoration Hardware</a></h4><ul> <li>Restoration Hardware (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>) is on watch after Citi <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Citi+Downgrades+Restoration+Hardware+%28RH%29+to+Neutral/13121003.html\" target=\"_blank\">lowers</a> its rating to Neutral from Buy.</li> <li>The firm slashes its price target on RH&nbsp;to $63 from $76 on its view that the company's debt-financed buyback activity poses a risk.</li> <li>RH <font color='red'>-2.82%</font> premarket to $72.00. Shares of RH are up 141% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280539\" data-linked=\"Citi warns on Restoration Hardware\" data-tweet=\"$RH - Citi warns on Restoration Hardware https://seekingalpha.com/news/3280539-citi-warns-on-restoration-hardware?source=tweet\" data-url=\"https://seekingalpha.com/news/3280539-citi-warns-on-restoration-hardware\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280538\" data-ts=\"1500901907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280538-mabvax-to-explore-strategic-alternatives-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax to explore strategic alternatives; shares up 1% premarket</a></h4><ul><li>Thinly traded nano cap MabVax Therapeutics Holdings (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a>) perks up&nbsp;<font color='green'>1%</font>&nbsp;on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16893830-mabvax-therapeutics-board-directors-authorizes-company-explore-strategic-alternatives\" target=\"_blank\">announcement </a>that it board has authorized the engagement of a financial advisor to assist it in exploring/evaluating strategic options aimed at boosting shareholder value.</li><li>Alternatives could include, but are not limited to, being acquired, selling certain assets, a merger or a licensing deal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280538\" data-linked=\"MabVax to explore strategic alternatives; shares up 1% premarket\" data-tweet=\"$MBVX $MBVXQ - MabVax to explore strategic alternatives; shares up 1% premarket https://seekingalpha.com/news/3280538-mabvax-to-explore-strategic-alternatives-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3280538-mabvax-to-explore-strategic-alternatives-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280537\" data-ts=\"1500901863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280537-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CYTX' title='Cytori Therapeutics Inc'>CYTX</a>&nbsp;<font color='red'>-61%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3280521-cytoris-habeo-cell-therapy-flunks-pivotal-scleroderma-study-shares-plummet-59-percent\" target=\"_blank\">announcing</a> 24 and 48 week results from the STAR trial of Habeo Cell Therapy in patients with scleroderma.</li><li><a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a>&nbsp;<font color='red'>-20%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3280478-hibbett-sports-posts-q2-sales-update\" target=\"_blank\">reporting</a> Q2 preliminary results.</li><li><a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280537\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$PSTV $HIBB $TEAR - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3280537-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3280537-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280531\" data-ts=\"1500901263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YTRA\" target=\"_blank\">YTRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280531-yatra-online-acquires-air-travel-bureau\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yatra Online acquires Air Travel Bureau</a></h4><ul> <li>Yatra Online (NASDAQ:<a href='https://seekingalpha.com/symbol/YTRA' title='Yatra Online, Inc.'>YTRA</a>) announces that it has entered into a definitive agreement, through a subsidiary to acquire&nbsp;Air Travel Bureau Ltd. for an undisclosed amount.</li> <li>Air Travel is India's largest independent corporate travel services provider.</li> <li>\"This acquisition significantly strengthens our position in the large and growing corporate travel market in India. We believe that as a combined entity, we are now the largest corporate travel services platform in India by Gross Bookings,\" says Yatra Online CEO Dhruv Shringi.</li> <li>The boards of both companies have approved the transaction.</li>  <li>YTRA  <font color='green'>+9.25%</font> premarket to  $12.05.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16893566-yatra-attains-leadership-position-corporate-travel-acquisition-air-travel-bureau-ltd\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280531\" data-linked=\"Yatra Online acquires Air Travel Bureau\" data-tweet=\"$YTRA - Yatra Online acquires Air Travel Bureau https://seekingalpha.com/news/3280531-yatra-online-acquires-air-travel-bureau?source=tweet\" data-url=\"https://seekingalpha.com/news/3280531-yatra-online-acquires-air-travel-bureau\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280529\" data-ts=\"1500901172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMSA\" target=\"_blank\">FMSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280529-fairmount-santrol-signs-lease-for-165m-tons-of-permian-basin-sand-reserves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fairmount Santrol signs lease for 165M tons of Permian Basin sand reserves</a></h4><ul>     <li>Fairmount Santrol (NYSE:<a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a>)&nbsp;<font color='green'>+2.9%</font> premarket following news it <a href=\"https://seekingalpha.com/pr/16893649-fairmount-santrol-announces-signing-long-term-lease-development-permian-basin-sand-facility\" target=\"_blank\">signed a 40-year lease</a> for more than 3K acres in the Permian Basin containing reserves of ~165M tons of fine-grade sand.</li>     <li>FMSA plans to build a mine and processing facility on the leased land with annual production capacity of ~3M tons; it expects sand production by the Q2 2018.</li>     <li>FMSA also says it will reopen its Shakopee, Minn., mine and sand processing plant, due to increased demand; the facility will have annual capacity of ~700K tons, and the Company expects the plant to be operational by Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280529\" data-linked=\"Fairmount Santrol signs lease for 165M tons of Permian Basin sand reserves\" data-tweet=\"$FMSA - Fairmount Santrol signs lease for 165M tons of Permian Basin sand reserves https://seekingalpha.com/news/3280529-fairmount-santrol-signs-lease-for-165m-tons-of-permian-basin-sand-reserves?source=tweet\" data-url=\"https://seekingalpha.com/news/3280529-fairmount-santrol-signs-lease-for-165m-tons-of-permian-basin-sand-reserves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280527\" data-ts=\"1500901061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280527-seattle-genetics-teams-up-roches-genentech-to-evaluate-adc-tecentriq-combo-in-difficult-to\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seattle Genetics teams up with Roche&#39;s Genentech to evaluate ADC/Tecentriq combo in difficult-to-treat form of breast cancer; shares up 1% premarket</a></h4><ul><li>Seattle Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket, albeit on only 600 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16893778-seattle-genetics-announces-clinical-collaboration-expand-therapeutic-evaluation-sgn-liv1a\" target=\"_blank\">announcement</a> that it will collaborate with Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) Genentech on the combination of SGN-LIV1A, an antibody-drug conjugate &#40;ADC&#41;, and TECENTRIQ (atezolizumab) in patients with triple negative breast cancer &#40;TNBC&#41;, a form of the disease with a poor prognosis since the cancer does not express proteins that are known therapeutic targets.</li><li>The combo will be evaluated in a 45-subject Phase 1b/2 study in a second-line setting in TNBC patients who have not received an immunotherapy. Genentech will manage the trial.</li><li>Seattle Genetics retains global development and commercialization rights to SGN-LIV1A, an ADC that targets a protein expressed by most metastatic breast cancers called LIV-1. The cytotoxic payload is called monomethyl auristatin E &#40;MMAE&#41;. It employs the same technology as ADCETRIS (brentuximab).</li></ul><div class=\"tiny-share-widget\" data-id=\"3280527\" data-linked=\"Seattle Genetics teams up with Roche&#39;s Genentech to evaluate ADC/Tecentriq combo in difficult-to-treat form of breast cancer; shares up 1% premarket\" data-tweet=\"$SGEN $SGEN $RHHBY - Seattle Genetics teams up with Roche&#39;s Genentech to evaluate ADC/Tecentriq combo in difficult-to-treat form of breast cancer; shares up 1% premarket https://seekingalpha.com/news/3280527-seattle-genetics-teams-up-roches-genentech-to-evaluate-adc-tecentriq-combo-in-difficult-to?source=tweet\" data-url=\"https://seekingalpha.com/news/3280527-seattle-genetics-teams-up-roches-genentech-to-evaluate-adc-tecentriq-combo-in-difficult-to\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280521\" data-ts=\"1500899908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTX\" target=\"_blank\">CYTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280521-cytoris-habeo-cell-therapy-flunks-pivotal-scleroderma-study-shares-plummet-59-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cytori&#39;s Habeo Cell Therapy flunks pivotal scleroderma study; shares plummet 59% premarket</a></h4><ul><li>Nano cap Cytori Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYTX' title='Cytori Therapeutics Inc'>CYTX</a>) is down&nbsp;<font color='red'>59%</font>&nbsp;premarket on average volume after <a href=\"https://seekingalpha.com/pr/16893827-cytori-announces-top-line-24-48-week-results-star-trial-habeo-cell-therapy-patients\" target=\"_blank\">reporting </a>that its pivotal <a href=\"https://clinicaltrials.gov/ct2/show/NCT02396238?cond=Scleroderma&amp;titles=STAR&amp;lead=cytori+therapeutics&amp;rank=1\" target=\"_blank\">STAR </a>study assessing Habeo Cell Therapy for the treatment of scleroderma failed to achieve its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48.</li><li>The company says there were \"clinically meaningful\" improvements in both the primary and secondary endpoints of both hand function and scleroderma-associated functional disability compared to placebo in a subgroup of patients with diffuse cutaneous scleroderma, a more severe form of the disease.</li><li>It will continue its analysis of the data before determining the next steps.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3048246-cytoris-late-stage-slceroderma-study-eccsminus-50-continue-planned\" target=\"_blank\">Cytori's late-stage slceroderma study of ECCS-50 to continue as planned</a> (Jan. 25, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280521\" data-linked=\"Cytori&#39;s Habeo Cell Therapy flunks pivotal scleroderma study; shares plummet 59% premarket\" data-tweet=\"$CYTX $PSTV - Cytori&#39;s Habeo Cell Therapy flunks pivotal scleroderma study; shares plummet 59% premarket https://seekingalpha.com/news/3280521-cytoris-habeo-cell-therapy-flunks-pivotal-scleroderma-study-shares-plummet-59-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3280521-cytoris-habeo-cell-therapy-flunks-pivotal-scleroderma-study-shares-plummet-59-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280518\" data-ts=\"1500899601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNC\" target=\"_blank\">ARNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280518-arconic-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arconic beats by $0.06, beats on revenue</a></h4><ul><li>Arconic (NYSE:<a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a>): Q2 EPS of $0.32 <font color='green'>beats by $0.06</font>.</li><li>Revenue of $3.26B (+0.9% Y/Y) <font color='green'>beats by $80M</font>.</li><li>Shares <font color='green'>+4%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16893921-arconic-reports-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280518\" data-linked=\"Arconic beats by $0.06, beats on revenue\" data-tweet=\"$ARNC - Arconic beats by $0.06, beats on revenue https://seekingalpha.com/news/3280518-arconic-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3280518-arconic-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280515\" data-ts=\"1500899569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LII\" target=\"_blank\">LII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280515-on-lennoxs-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Lennox&#39;s Q2</a></h4><ul>     <li>Lennox (NYSE:<a href='https://seekingalpha.com/symbol/LII' title='Lennox International Inc.'>LII</a>) reports&nbsp;Residential Heating &amp; Cooling segment revenue rose 14% to $654M in <a href=\"https://seekingalpha.com/pr/16893801-lennox-international-reports-record-revenue-profit-second-quarter\" target=\"_blank\">Q2</a>.</li>     <li>Commercial Heating &amp; Cooling segment revenue increased 2% to $259M.</li>     <li>Refrigeration segment revenue down 1% to $190M.</li>     <li>Gross margin rate flat at 30.9%.</li>     <li>Residential Heating &amp; Cooling operating margin rate +130 bps to 21.5%.</li>     <li>Commercial Heating and Cooling operating margin rate down 140 bps to 17.3%.</li>     <li>Refrigeration operating margin rate slipped 30 bps to 11.4%<b>.</b></li>     <li><b>FY2017 Guidance</b>: Revenue: +4% to +7%; GAAP EPS: $7.73 to $8.13; Adjusted EPS: $7.75 to $8.15; Tax rate: ~31% to 32%; Share count: ~42M to 43M; Capex: ~$100M; Stock repurchase: $250M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280515\" data-linked=\"More on Lennox&#39;s Q2\" data-tweet=\"$LII - More on Lennox&#39;s Q2 https://seekingalpha.com/news/3280515-on-lennoxs-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280515-on-lennoxs-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280508\" data-ts=\"1500898192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280508-nektar-teams-up-lilly-to-develop-autoimmune-candidate-nktrminus-358\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar teams up with Lilly to develop autoimmune candidate NKTR-358</a></h4><ul><li>Nektar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a>) inks a <a href=\"https://seekingalpha.com/pr/16893743-lilly-nektar-therapeutics-announce-alliance-develop-commercialize-nktrminus-358-novel\" target=\"_blank\">strategic collaboration</a> with Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) to co-develop NKTR-358, a candidate to potentially treat a range of autoimmune and other chronic inflammatory conditions.</li><li>The company refers to NKTR-358 as a resolution therapeutic that may bring the immune system back into balance by activating regulatory T cells via targeting the interleukin (IL-2) receptor complex in the body.</li><li>Under the terms of the agreement, Nektar will receive an upfront payment of $150M, up to $250M in milestones and double-digit royalties on net sales. The companies will co-develop NKTR-358 with Nektar responsible for Phase 1. Phase 2 costs will be shared on a 75/25 basis with Lilly leading. Nektar will have the option to participate in Phase 3 on an indication-specific basis and has the option to co-promote in the U.S. under certain conditions. Lilly will be responsible for all global commercialization costs.</li><li>Lilly expects to record a $0.09/share charge this year for acquired in-process R&amp;D so its 2017 EPS guidance will be reduced by this amount.</li><li>NKTR is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280508\" data-linked=\"Nektar teams up with Lilly to develop autoimmune candidate NKTR-358\" data-tweet=\"$NKTR $NKTR $LLY - Nektar teams up with Lilly to develop autoimmune candidate NKTR-358 https://seekingalpha.com/news/3280508-nektar-teams-up-lilly-to-develop-autoimmune-candidate-nktrminus-358?source=tweet\" data-url=\"https://seekingalpha.com/news/3280508-nektar-teams-up-lilly-to-develop-autoimmune-candidate-nktrminus-358\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280502\" data-ts=\"1500897925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DKS\" target=\"_blank\">DKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280502-weak-results-from-hibbett-sports-hit-sports-retail-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak results from Hibbett Sports hit sports retail sector</a></h4><ul> <li>Dick's Sporting Goods (NYSE:<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a>) is <font color='red'>down 3.88%</font> and Big 5 Sporting Goods (NASDAQ:<a href='https://seekingalpha.com/symbol/BGFV' title='Big 5 Sporting Goods Corporation'>BGFV</a>) is <font color='red'>3.96% lower</font> after Hibbett Sports posts preliminary Q2 results below expectations.</li> <li>Hibbett says \"very challenging\" sales trends led to a 10% drop in comparable sales.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280478-hibbett-sports-posts-q2-sales-update\" target=\"_blank\">Hibbett Sports posts Q2 sales update</a> (July 24)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280502\" data-linked=\"Weak results from Hibbett Sports hit sports retail sector\" data-tweet=\"$DKS $DKS $BGFV - Weak results from Hibbett Sports hit sports retail sector https://seekingalpha.com/news/3280502-weak-results-from-hibbett-sports-hit-sports-retail-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3280502-weak-results-from-hibbett-sports-hit-sports-retail-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280492\" data-ts=\"1500897134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280492-webmd-provides-preliminary-q2-results-shares-ahead-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD provides preliminary Q2 results; shares ahead 20% premarket</a></h4><ul> <li>WebMD Health (NASDAQ:<a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a>) <a href=\"https://seekingalpha.com/pr/16893732-webmd-provides-preliminary-second-quarter-financial-results\" target=\"_blank\">announces</a> preliminary financial results for the three months ended June 30, 2017.</li>  <li>Q2 Revenue is expected to be ~$176M, above previously stated Q2 guidance of $170M to $173M.</li><li>Net income for Q2 is expected to be ~$18.9M, above prior Q2 guidance of $16.9M to $18.5M. Q2 EPS is expected to be $0.43.</li><li>Q2 Adjusted EBITDA is expected to be ~$54M, higher than the previous Q2 guidance of $49M to $51M.</li><li>Shares are up&nbsp;<font color='green'>20%</font>&nbsp;premarket on average volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280492\" data-linked=\"WebMD provides preliminary Q2 results; shares ahead 20% premarket\" data-tweet=\"$WBMD - WebMD provides preliminary Q2 results; shares ahead 20% premarket https://seekingalpha.com/news/3280492-webmd-provides-preliminary-q2-results-shares-ahead-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3280492-webmd-provides-preliminary-q2-results-shares-ahead-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280484\" data-ts=\"1500896093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNCA\" target=\"_blank\">GNCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280484-genocea-reports-positive-top-line-12-month-phase-2b-data-for-genminus-003-in-genital-herpes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genocea reports positive top-line 12-month Phase 2b data for GEN-003 in genital herpes; shares ahead 17% premarket</a></h4><ul> <li>Genocea Biosciences&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) <a href=\"https://seekingalpha.com/pr/16893719-genocea-reports-positive-top-line-12-month-phase-2b-data-genminus-003-genital-herpes\" target=\"_blank\">announces</a> positive 12-month top-line data from the Phase 2b clinical trial for <a href=\"https://www.genocea.com/pipeline/gen003-for-genital-herpes/\" target=\"_blank\">GEN-003</a>, its immunotherapy candidate for patients with <a href=\"https://medlineplus.gov/genitalherpes.html\" target=\"_blank\">genital herpes</a>.</li>     <li>In this 131-subject Phase 2b clinical trial, GEN-003 reduced the median genital lesion rate versus placebo by 49% and 37% and&nbsp;the median number of recurrences versus placebo by 63% and 50%&nbsp;over the 12 months&rsquo; post dosing at the 60 &micro;g per antigen / 50 &micro;g of adjuvant dose and&nbsp;60 &micro;g per antigen / 75 &micro;g of adjuvant dose, respectively.</li><li>Importantly, these results were achieved at the Phase 3 dose and expected Phase 3 primary endpoint. Other clinical endpoints for this dose improved or were consistent with previously reported positive data. No changes were observed to the previously established safety profile of GEN-003.</li>  <li>Genocea management will host a conference call and webcast at 8 a.m. ET to review these data.</li>  <li>In September 2016, Genocea reported that the trial achieved its primary endpoint, with GEN-003 demonstrating a statistically significant reduction in the rate of viral shedding in the 60 &micro;g per antigen / 50 &micro;g of adjuvant dose group compared to both baseline and placebo.</li><li>Shares are up&nbsp;<font color='green'>17%</font>&nbsp;premarket on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280484\" data-linked=\"Genocea reports positive top-line 12-month Phase 2b data for GEN-003 in genital herpes; shares ahead 17% premarket\" data-tweet=\"$GNCA - Genocea reports positive top-line 12-month Phase 2b data for GEN-003 in genital herpes; shares ahead 17% premarket https://seekingalpha.com/news/3280484-genocea-reports-positive-top-line-12-month-phase-2b-data-for-genminus-003-in-genital-herpes?source=tweet\" data-url=\"https://seekingalpha.com/news/3280484-genocea-reports-positive-top-line-12-month-phase-2b-data-for-genminus-003-in-genital-herpes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280477\" data-ts=\"1500895172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280477-sarepta-readies-250m-stock-offering-shares-slip-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta readies $250M stock offering; shares slip 2% premarket</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <a href=\"https://seekingalpha.com/pr/16893725-sarepta-therapeutics-announces-proposed-250-million-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of $250M of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund clinical trials, commercialization, manufacturing and business development activities and general corporate purposes.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280477\" data-linked=\"Sarepta readies $250M stock offering; shares slip 2% premarket\" data-tweet=\"$SRPT - Sarepta readies $250M stock offering; shares slip 2% premarket https://seekingalpha.com/news/3280477-sarepta-readies-250m-stock-offering-shares-slip-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3280477-sarepta-readies-250m-stock-offering-shares-slip-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280476\" data-ts=\"1500895019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCN\" target=\"_blank\">OCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280476-new-residential-and-ocwen-come-to-terms-on-msr-transfers-ocwen-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Residential and Ocwen come to terms on MSR transfers; Ocwen up 10%</a></h4><ul><li>Under the deal, Ocwen (NYSE:<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a>) will transfer to New Residential (NYSE:<a href='https://seekingalpha.com/symbol/NRZ' title='New Residential Investment Corp.'>NRZ</a>) about $110B UPB of MSRs. In exchange, New Residential will pay Ocwen restructuring fee payments of up to roughly $400M. Subject to approvals, the transfers could begin as soon as September and continue into next year.</li><li>Alongside, New Residential has agreed for Ocwen to subservice the transferred mortgages for five years.</li><li>Also alongside, New Residential will become a part owner of Ocwen, agreeing to pay $13.9M for a 4.9% stake.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261730-ocwen-new-residential-confirm-deal-talks-press-release\" target=\"_blank\">Ocwen and New Residential confirm deal talks in press release</a> (May 1)</li><li>Source: <a href=\"https://seekingalpha.com/pr/16893684-new-residential-ocwen-financial-announce-agreement-relating-mortgage-servicing-rights\" target=\"_blank\">Press Release</a></li><li>Ocwen&nbsp;<font color='green'>+10.3%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3280476\" data-linked=\"New Residential and Ocwen come to terms on MSR transfers; Ocwen up 10%\" data-tweet=\"$OCN $OCN $NRZ - New Residential and Ocwen come to terms on MSR transfers; Ocwen up 10% https://seekingalpha.com/news/3280476-new-residential-and-ocwen-come-to-terms-on-msr-transfers-ocwen-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3280476-new-residential-and-ocwen-come-to-terms-on-msr-transfers-ocwen-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>136&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280472\" data-ts=\"1500894106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280472-webmd-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD trading halted pending news</a></h4><ul><li>Nasdaq has suspended trading in WebMD (NASDAQ:<a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a>) pending news, which should be its acquisition by KKR.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280435-reuters-kkr-nears-deal-buy-webmd\" target=\"_blank\">Reuters: KKR nears deal to buy WebMD</a> (July 24)</li><li><strong>Update</strong>: WebMD confirms that KKR will acquire it for $66.50/share in cash. Preliminary Q2 EBITDA is $54M versus guidance of $49M - 51M on revenues of $176M (consensus: $171.6M). Shares are up&nbsp;<font color='green'>18%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280472\" data-linked=\"WebMD trading halted pending news\" data-tweet=\"$WBMD - WebMD trading halted pending news https://seekingalpha.com/news/3280472-webmd-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3280472-webmd-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280464\" data-ts=\"1500893838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280464-hasbro-down-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hasbro down post Q2 results</a></h4><ul>     <li>Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>) reports revenue rose 11% in <a href=\"https://seekingalpha.com/pr/16893673-hasbro-reports-revenue-operating-profit-net-earnings-growth-second-quarter-2017\" target=\"_blank\">Q2</a>&nbsp;due to growth in Franchise Brands,&nbsp;Hasbro Gaming&nbsp;and Partner Brands.</li>     <li>U.S. and&nbsp;Canada revenue grew 16% to 494.4M.</li>     <li>International revenue increased $426.6M, led by 18% growth in Asia Pacific.</li>     <li>Entertainment and Licensing revenue slipped 1% to $51.5M.</li>     <li>Franchise brand revenue expanded 21% to $545.7M and Partner brand revenue +1% to $230M.</li>     <li>Hasbro gaming revenue increased 6% to $133.9M whereas Emerging brands fell 14% to $62.9M for the quarter.</li>     <li>Operating margin rate grew 60 bps to 10.3%.</li>     <li>&ldquo;The Hasbro team executed another very strong quarter across the Brand Blueprint. Story-led brands and innovative brand initiatives drove double-digit revenue growth and an increase in operating profit margin,&rdquo; said&nbsp;Brian Goldner, Hasbro&rsquo;s chairman and chief executive officer. &ldquo;Franchise Brand,&nbsp;Hasbro Gaming&nbsp;and Partner Brand revenues grew year-over-year, and revenue increased across all geographic regions. We entered the important second half of the year with strong consumer momentum, a robust and diverse entertainment slate and compelling new brand initiatives.&rdquo;</li>     <li>HAS&nbsp;<font color='red'>-1.25%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280464\" data-linked=\"Hasbro down post Q2 results\" data-tweet=\"$HAS - Hasbro down post Q2 results https://seekingalpha.com/news/3280464-hasbro-down-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3280464-hasbro-down-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280459\" data-ts=\"1500893262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMX\" target=\"_blank\">BPMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280459-biopharmx-sells-shares-to-institutional-investors-0_36\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioPharmX sells shares to institutional investors at $0.36</a></h4><ul><li>BioPharmX (NYSEMKT:<a href='https://seekingalpha.com/symbol/BPMX' title='BioPharmX Corporation'>BPMX</a>) inks an <a href=\"https://seekingalpha.com/filing/3631856\" target=\"_blank\">agreement </a>with certain institutional investors to sell 5.5M shares of common stock at $0.36 per share, almost a 22% discount to Friday's close of $0.46.</li><li>Net proceeds of ~$1.9M will fund pipeline development, working capital and general corporate purposes.</li><li>The transaction should close today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280459\" data-linked=\"BioPharmX sells shares to institutional investors at $0.36\" data-tweet=\"$BPMX - BioPharmX sells shares to institutional investors at $0.36 https://seekingalpha.com/news/3280459-biopharmx-sells-shares-to-institutional-investors-0_36?source=tweet\" data-url=\"https://seekingalpha.com/news/3280459-biopharmx-sells-shares-to-institutional-investors-0_36\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280453\" data-ts=\"1500891979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRM\" target=\"_blank\">NDRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280453-neuroderm-to-be-bought-mitsubishi-tanabe-pharma-for-39-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroDerm to be bought by Mitsubishi Tanabe Pharma for $39/share</a></h4><ul>     <li>NeuroDerm (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRM' title='NeuroDerm'>NDRM</a>) <font color='green'>+14.7%</font>&nbsp;premarket after <a href=\"https://seekingalpha.com/pr/16893594-neuroderm-enters-definitive-agreement-acquired-mitsubishi-tanabe-pharma-corporation-us-1_1\" target=\"_blank\">agreeing to be acquired</a> by Japan's Mitsubishi Tanabe Pharma (<a href='https://seekingalpha.com/symbol/MTZPY' title='Mitsubishi Tanabe Pharma Corp. ADR'>OTCPK:MTZPY</a>) for $39/share, a 17% premium over Friday's closing price and implying a ~$1.1B equity value.</li>     <li>The deal is the <a href=\"http://www.globes.co.il/en/article-israeli-pharma-co-neuroderm-sold-for-11b-1001198365\" target=\"_blank\">largest ever</a> acquisition of an Israeli pharmaceuticals company.</li>     <li>The Japanese drugmaker says it will leverage  NDRM's Parkinson's disease drug product that has begun clinical  trials in the U.S. and Europe.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280453\" data-linked=\"NeuroDerm to be bought by Mitsubishi Tanabe Pharma for $39/share\" data-tweet=\"$NDRM $NDRM $MTZPY - NeuroDerm to be bought by Mitsubishi Tanabe Pharma for $39/share https://seekingalpha.com/news/3280453-neuroderm-to-be-bought-mitsubishi-tanabe-pharma-for-39-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3280453-neuroderm-to-be-bought-mitsubishi-tanabe-pharma-for-39-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280449\" data-ts=\"1500890498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHG\" target=\"_blank\">PHG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280449-koninklijke-philips-nv-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Koninklijke Philips NV reports Q2 results</a></h4><ul><li>Koninklijke Philips NV (NYSE:<a href='https://seekingalpha.com/symbol/PHG' title='Koninklijke Philips NV'>PHG</a>): Q2 EPS of&nbsp;&euro;0.17</li><li>Revenue of&nbsp;&euro;4.29B (+3.9% Y/Y)</li><li>Shares <font color='green'>+3.35%</font> PM.</li><li><a href=\"https://www.philips.com/static/qr/2017/q2/philips-second-quarter-results-2017-report.pdf\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280449\" data-linked=\"Koninklijke Philips NV reports Q2 results\" data-tweet=\"$PHG - Koninklijke Philips NV reports Q2 results https://seekingalpha.com/news/3280449-koninklijke-philips-nv-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3280449-koninklijke-philips-nv-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:01 AM </div></div></li>","count":60,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}